Duchenne News Tags: Satellos Bioscience

February 12, 2026
On February 12, 2026, Satellos Bioscience Inc, announced that the first participant has been dosed in BASECAMP, a three-month, randomized, double-blind, placebo-controlled, proof-of-concept, Phase 2 pediatric study of SAT-3247 for...

Jett Foundation’s Silver Soirée
Thursday, June 11, 2026 | 5:30PM
Granite Links | Quincy, MA